At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALPN Alpine Immune Sciences Inc.
Halted 05-17 16:00:00 EDT
64.97
+0.01
+0.02%
盘后64.99
+0.02+0.03%
19:22 EDT
High65.00
Low64.97
Vol4.29M
Open64.98
D1 Closing64.96
Amplitude0.05%
Mkt Cap4.46B
Tradable Cap2.69B
Total Shares68.60M
T/O278.64M
T/O Rate10.34%
Tradable Shares41.48M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Alpine Immune Sciences Price Target Maintained With a $65.00/Share by Wedbush
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.